Commenting on the provisional deal reached by the European Parliament and Council on the Critical Medicines Act, EFPIA Director General Nathalie Moll said:
“The provisional agreement is a welcome step towards strengthening the resilience and security of supply of critical medicines in Europe, while preserving competitiveness and patient access across Europe.
With the exception of certain targeted areas, the scope of the legislation appears to remain limited to critical medicines and/or critical medicines with vulnerabilities. This shows that a risk-based approach has been taken by policymakers.
That a more pragmatic and flexible stance has been taken on ‘EU preference’ criteria compared to earlier proposals, and that the focus remains on genuinely critical medicines, is also positive.”
